Trial Profile

A Phase II Study Evaluating the Efficacy and Safety of Combination of CPGJ602 and Chemotherapy as First Line Treatment in KRAS/NRAS/BRAF Wild-type, Metastatic Colorectal Cancer Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CPGJ-602 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Cetuximab
Indications Colorectal cancer
Focus Therapeutic Use
Sponsors Sunshine Guojian Pharmaceutical

Most Recent Events

07 Jun 2022 Results (n=76; as of 30 Dec 2021) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
16 Aug 2021 Planned End Date changed from 1 Dec 2021 to 30 Mar 2022.
16 Aug 2021 Planned primary completion date changed from 4 Aug 2021 to 30 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com